Southlake Biotech Renibus Therapeutics Garners $33M in Bridge Financing

Southlake-based biotech Renibus Therapeutics has received $33 million in bridge financing consisting of a $23 million SAFE (Simple Agreement for Future Equity) offering and $10 million pursuant to the first tranche of a $30 million term loan with Oxford Finance, reports Finmes.

Renibus is a clinical-stage biotech company developing innovative products for cardio-renal diseases. Founded in 2015, Renibus has three drugs in its pipeline in various phases of trials.

According to FinSMEs, the SAFE offering closed in July and August, and was led by existing investors and select new investors comprised of high-net-worth individuals and family offices.

It reported that under the terms of the credit facility with Oxford, the funds are available in three tranches of $10 million, for a total of up to $30 million. The term loan matures in October 2027 and includes a 24-month interest-only period that can be extended to 36 months under certain conditions, FinSMEs said.

The first tranche of $10 million closed in August. Renibus is under no obligation to draw additional funds in the future, according to the report.

Series A funding and a new CEO

Earlier this year, the biotech announced closing a $35 million Series A funding round that includes a $15 million extension led by “family offices specializing in biotech investments” to help fuel the development of three of its therapies.

Renibus also announced that co-founder and CEO Al Guillem would be transitioning to a role as executive chairman of the board. Frank Stonebanks, a former venture partner at healthcare-focused VC firm Wavemaker Three-Sixty Health, took over the CEO role.

“Renibus has arrived at a critical inflection point in its commitment to transform the prevention and treatment of kidney diseases,” said Stonebanks at the time.

The clinical-stage biopharmaceutical company says it is dedicated to treating, improving, and extending patients’ lives by developing products to prevent disease progression, improve outcomes, and protect against organ damage in cardio-renal diseases.

Get on the list.
Dallas Innovates, every day.

Sign up to keep your eye on what’s new and next in Dallas-Fort Worth, every day.

One quick signup, and you’re done.  

R E A D   N E X T

  • In this week's roundup of hires, promotions, and accolades in North Texas, you'll also find news from VERTESS, Mr. Cooper, Active Cyber, EarthX, SWK Holdings, and more. Plus, Fort Worth Mayor Mattie Parker makes an appointment to the city council's Entrepreneurship and Innovation Committee.

  • Renibus Therapeutics, which focuses on treatments for acute and chronic kidney diseases, announced closing a $35 million Series A funding round. Its new CEO, Frank Stonebanks, says "Renibus has arrived at a critical inflection point in its commitment to transform the prevention and treatment of kidney diseases."

  • A new GolfTEC training center has opened in Southlake to help duffers straighten their slices and handle their hooks.  The new 2,900-square-foot facility features four indoor training bays powered by TECSwing, using Foresight Sports simulators for lessons, club fitting, and practice. Each training bay is equipped with OptiMotion, a motion tracking innovation that "sets a new standard for how golf swings are measured and the way golf instruction is delivered," according to the company. Put off by your putting? The facility also has an indoor putting green with lessons utilizing TECPutt, a motion technology that analyzes face angle, loft, and path…

  • The Cancer Prevention & Research Institute of Texas has provided more than $3.1 billion in funding toward the development of cancer-fighting therapeutics, devices, diagnostics, and tools since 2010. It's now issued a call for startups and early-stage companies to apply for product development research grants for the 2023 fiscal year. “CPRIT’s mission is to invest in the research prowess of Texas institutions while expediting breakthroughs in cancer cures and prevention,” CEO Wayne Roberts said last May.

  • From right: DRC's Jorge Varela (far right) moderated a panel of industry experts including biotech C-level executive Hua Tu, Health Wildcatters CEO and co-founder Hubert Zajicek, and LH Capital Director Matt Crommett.

    "It takes time" to establish a track record, Jorge Varela says, and the region is starting to see a series of biotech successes and spinoffs that will elevate the region's profile as a biotech hub. According to a panel of experts at Urban Land Institute's 2022 spring meeting, here are factors drawing biotech to DFW.